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We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood of
eight Zambian individuals infected with non-B-clade human immunodeficiency virus type 1 (HIV-1). Hetero-
duplex mobility assay and partial sequence analysis of env and gag genes strongly suggests that all the HIV-
infected subjects were infected with clade C HIV-1. Six of eight C-clade HIV-infected individuals elicited CTL
activity specific for recombinant vaccinia virus-infected autologous targets expressing HIV gag-pol-env derived
from B-clade HIV-1 (IIIB). Recognition of individual recombinant HIV-1 B-clade vaccinia virus-infected
targets expressing gag, pol, or env was variable among the patients tested, indicating that cross-clade CTL
activity is not limited to a single HIV protein. These data demonstrate that HIV clade C-infected individuals
can mount vigorous HIV clade B-reactive CTL responses.
Globally circulating strains of human immunodeficiency vi-
rus type 1 (HIV-1) are known to exhibit extraordinary genetic
diversity (1, 4, 7, 12, 24). There are currently eight sequence
subtypes or clades (A to J), and one outlier group (O) of
HIV-1, which have been defined as distinct phylogenetic lin-
eages in evolutionary trees. The extent of HIV-1 sequence
diversity (11, 12, 21, 24), intraclade variability (15, 22), and
interclade recombination (1, 7, 22) all potentially affect the
efficacy of an HIV-1 vaccine.
In HIV vaccine development, a broadly cross-reactive im-
mune response capable of recognizing multiple HIV clades is
desirable. While neutralization of different HIV-1 clades by
HIV-infected patient sera is limited (14, 17, 19), some gp160-
specific human monoclonal antibodies neutralize multiple
clades of HIV-1 (18, 26, 27). Additionally, cross-reactive
CD41 T-cell proliferative responses have been observed in
HIV-1 B-clade-infected individuals which recognize HIV-1
gp120 V3 loop peptides from A, B, and D-clade viruses (5, 19).
Recently, broadly reactive cross-clade cytotoxic T-lympho-
cyte (CTL) activity was observed in four recipients of a recom-
binant canarypox/HIV-1 MN (clade B) gp160 vaccine (6). HIV
gp120 clade sequence variation can also influence target rec-
ognition by HIV gp120 peptide-specific CTL clones (29). In
this report, we demonstrate that CTLs from HIV C-clade-
infected individuals kill autologous targets expressing HIV-1
clade B-derived gag, pol, and/or env.
Study subjects (designated ZC01 to ZC13 [see Table 1])
were recruited from a voluntary HIV testing center at Project
San Francisco in Lusaka, Zambia (16). The duration of HIV
infection in the HIV-seropositive subjects (ZC01 to ZC08)
remains unknown. Antibodies to HIV-1 were detected by the
dipstick and Capillus tests as described elsewhere (16) and
confirmed with a commercial enzyme-linked immunosorbent
assay kit (Organon Teknika, Durham, N.C.). None of the pa-
tients met criteria for AIDS diagnosis (2), but some suffered
from malaria, tuberculosis, and/or other diseases and reported
symptoms such as weakness and/or adenopathy, which may
have been related to their HIV infections. All HIV-seronega-
tive donors (ZC09 to ZC13) were female partners in discor-
dant couples at the time of blood collection.
Peripheral blood mononuclear cells (PBMC) were isolated
from each of the HIV-infected Zambian study participants,
and the sequence subtypes of their infecting viruses were char-
acterized by heteroduplex mobility assay (HMA) (env) and
sequence analysis (gag). Figure 1a shows the env HMA profile
of an HIV-infected donor in the United States (USB01). The
HIV env region from USB01 is most closely related to the B3,
B1, and B2 clade standards but is divergent from the C1 to C4
clade standards. Figure 1b shows a more extensive analysis of
the HIV env region from Zambian subject ZC08. The HIV env
region from subject ZC08 was most closely related to the C2
and C1 standards but is divergent from the standards of all
other clades. These results are typical of viral env sequences
from all the HIV-infected Zambian study subjects and suggest
that the subjects were infected with C-clade HIV. To confirm
subtype classification in a second genomic region, we amplified
and partially sequenced a gag fragment (620 bp) from the
PBMC DNA of each HIV-infected study participant. Phyloge-
netic analysis (Fig. 2) indicates that all individuals were in-
fected with subtype C viruses. Concordance in two genomic
regions (3) strongly suggests that the study subjects were in-
fected with nonrecombinant subtype C viruses.
We next assessed the ability of CTLs from these HIV-1
C-clade-infected Zambians to recognize targets which express
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HIV-1 B-clade-derived antigens. To selectively restimulate
HIV clade B-specific CTL activity, we used UV/psoralen-inac-
tivated, autologous Epstein-Barr virus-transformed B lympho-
cytes (EBV-BCL) infected with the HIV B-clade vaccinia virus
recombinants VV-GPE (VV-ABT 408-6-1, containing clade B
HIV-1 IIIB gag, pol, and env; Therion Biologics, Cambridge,
Mass.) and VV-nef (containing HIV IIIB nef; gift of Andrew
McMichael, Oxford, United Kingdom). This technique is high-
ly effective in restimulating major histocompatibility complex
(MHC) class I-restricted HIV-specific CTLs from HIV-in-
fected individuals in vitro (9, 13). Freshly thawed donor PBMC
were added to the inactivated VV-GPE and VV-nef-infected
EBV-BCL at a ratio of 2 3 106 PBMC to 2 3 105 EBV-BCL/
well in complete RPMI supplemented with 25 ng of recombi-
nant human interleukin 7 (IL-7) per ml (Endogen, Cambridge,
Mass.) and 10% Lymphocult T-LF (IL-2 source; Biotest,
Dreiech, Germany) in a 24-well plate (Becton Dickinson,
Franklin Lakes, N.J.). The cultures were incubated for 7 days
in 5% CO2 at 37°C and fed at day 3 or 4 by exchanging 1 ml of
medium with complete RPMI plus IL-2.
Table 1 shows the CTL responses of eight clade C-infected
(ZC01 to ZC08) and five HIV-seronegative (ZC09 to ZC13)
donors to HIV-1 B-clade nef- and GPE-expressing autologous
EBV-BCL. Six of eight C-clade HIV-infected Zambians dem-
onstrated significant (i.e., $10% above the level of the vaccinia
virus control) HIV-1-specific CTL activity to HIV-1 clade B
VV-GPE. Marginal HIV-1-specific CTL activity to VV-nef was
detected in ZC02. No HIV-1-specific CTL responses were de-
tectable in the five HIV-seronegative donors.
To further define the specificity of cross-clade CTLs in the
clade C HIV-infected subjects, we examined the HIV-specific
CTL activity against B-clade HIV-1 gag, pol, and env individ-
ually. Autologous EBV-BCL were infected overnight with VV-
sc11 or HIV B-clade vaccinia virus recombinants, VV-GPE,
VV-gag, VV-pol, or VV-env (VV-gag and VV-pol were from
Andrew McMichael; VV-env [vPE16] was from Patricia Earl
and Bernard Moss, AIDS Research and Reference Program,
Division of AIDS, National Institute of Allergy and Infectious
Diseases) at a multiplicity of infection of 5 for use as targets in
a standard 51Cr release assay (20). Donor ZC08 (Fig. 3a)
demonstrated extensive cross-clade HIV-specific CTL re-
FIG. 1. (a) DNA from an HIV-infected individual in the United States (USB01) was analyzed as described elsewhere (4) by HMA using the ED3, ED14, ES7, and
ES8 primers and HIV-1 envelope standards (AIDS Research and Reference Reagent Program) to determine the relatedness of this individual’s HIV proviral env
sequence to clade B and C env standards. (b) DNA from an HIV-infected Zambian donor (ZC08) was analyzed by HMA as for panel a to determine the relatedness
of the HIV env sequence to clade A to G env standards. Lanes: MW, molecular weight standards; S/S, PCR products in the absence of clade standards; DS, DNA
standards.
FIG. 2. Phylogenetic relationships of the Zambian viruses (boxed) in compar-
ison to representatives of HIV-1 group M subtypes A to H from the database. Par-
tial gag sequences were amplified by nested PCR from uncultured patient PBMC
DNA (outer primers: PBS1A, 59-TTTGCCTGTACTGGGTCTCTCTGGTT-
39, and CgagA, 59-TGATAAAACCTCCAATTCCCCCTAT-39; inner primers:
PBS1C, 59-GCTTAAGCCTCAATAAAGCTTGCCTT-39, and CgagB, 59-AAT
ACTGTATCATCTGCTCCTGTAT-39) and sequenced either directly or after
being subcloned into pCRII by T/A overhang. Nucleotide sequences were aligned by
using CLUSTAL (8), with minor manual adjustments. Pairwise evolutionary dis-
tances were estimated by Kimura’s two-parameter method (10) to correct for su-
perimposed hits. Phylogenetic trees were constructed by the neighbor-joining
method (23), and their reliability was estimated from 1,000 bootstrap replicates.
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sponses (i.e., greater than 10% above background sc11 specific
lysis) reactive with B-clade gag-, pol-, and env-expressing target
cells. In ZC08, both gag- and pol-expressing targets were lysed
(20% at a 1:1 effector-to-target [E:T] ratio), and the env
response was similarly high (20% at an E:T ratio of 5:1).
Further analysis of cross-clade CTL reactivity in HIV clade
C-infected donors ZC01, ZC05, and ZC06 revealed similar
variability of cross-clade recognition to ZC08 (Fig. 3b). Do-
nors ZC08 and ZC06 responded to clade B gag-, pol-, and
env-expressing targets, while ZC05 responded only to clade
B gag-expressing targets. Donor ZC01 failed to recognize
clade B GPE-infected targets (Table 1) but demonstrated
marginal (10% specific lysis) reactivity to B-clade pol-ex-
pressing targets. A comparative analysis of the B-clade-
specific CTL responses in eight clade B HIV-1-infected sub-
jects and the clade C-infected subjects demonstrated both
comparable levels of killing and comparable specificity pro-
files (data not shown). Taken together, these data demon-
strate both the existence and variability of cross-clade reac-
tivity of HIV-specific CTL activity between HIV-1 clades B
and C in HIV C-clade-infected Zambians. Whether the clade
C-infected donors in this study elicit cross-clade CTL activity
against the other known HIV viral clades, i.e., A and D to J, or
group O, is currently being studied.
The conservation of CTL epitopes between different HIV-1
clade variants, as well as the host MHC profile, is likely to
influence cross-clade CTL recognition. An examination of se-
quences from the Los Alamos National Laboratory database
revealed many conserved CTL epitopes between HIV HxB2r
(B clade), Zam18, -19, and -20 (Zambian C-clade isolates), and
ETH2220 (Ethiopian C-clade isolate). In HIV-1 gag, 16 CTL
epitopes completely conserved between HxB2r and Zam18 to
-20 have been identified (9 of 39 known p24 epitopes, 6 of 22
p17 epitopes, and 1 of 2 p15 epitopes). In HIV-1 pol, 9 CTL
epitopes completely conserved between HxB2r and ETH2220
(C-clade isolate) are known (0 of 3 protease epitopes, 8 of 31
reverse transcriptase epitopes, and the 1 integrase epitope). In
HIV-1 env, however, only 7 CTL epitopes fully conserved
between HxB2r and Zam18 to -20 have been described (3 of 41
gp120 epitopes and 4 of 24 gp41 epitopes). This is likely to be
an underestimate of functional conservation, since some CTL
epitope positions are tolerant of substitution (20, 25). The
completely conserved gag, pol, and env CTL epitopes bind a
variety of MHC class I alleles, the majority of which are found
in south-central Africa (HLA-A2, B7, B8, B14, B35, and
B57) (28). The two HIV-infected individuals in this study
who failed to elicit cross-clade killing either are poor re-
sponders or express different MHC class I haplotypes, which
bind CTL epitopes not conserved between HIV-1 B- and
C-clade viruses.
Whether cross-clade CTL activity can be primed depends on
two important factors: the viral-sequence diversity of the dif-
ferent clades (11, 12, 21, 24) and the MHC class I profile in the
infected host or vaccine recipient (6, 29). The generation of an
HIV vaccine designed to elicit HIV-specific CTL activity must
take these factors into account to prime effective intraclade
and interclade CTL activity.
FIG. 3. Zambian subject ZC08 elicits HIV-1 B clade-specific CTL activity against HIV-1 gag, pol, env, and GPE (a), and Zambian subjects ZC08, ZC06, ZC05,
and ZC01 elicit variable HIV-1 B clade-specific CTL responses (b). A 51Cr release assay was performed by using uninfected, vaccinia virus control (sc11), and HIV-1
clade B gag, pol, env, or GPE recombinant vaccinia virus-infected EBV-BCL as targets. For panel a, E:T ratios of 25, 12.5, 6.25, 3.1, 1.5, and 0.75:1 were used. For panel
b, the E:T ratios were as follows: ZC08, 25:1; ZC06, 25:1; ZC05, 25:1; ZC01, 20:1. Percent specific lysis was calculated as described for Table 1. Unlabeled sc11-infected
EBV-BCL were added to each well at a 30:1 unlabeled-to-labeled cell ratio to reduce vaccinia virus-specific background. Lysis of uninfected target cells was below 5%
at each E:T ratio tested.






ZC01 (1) 0.2 NT 5.1
ZC02 (1) 16.4 24.8 58.5
ZC03 (1) 6.8 NT 13.1
ZC04 (1) 0.0 NT 34.1
ZC05 (1) 6.7 NT 28.3
ZC06 (1) 9.4 NT 62.4
ZC07 (1) 4.3 3.7 31.0
ZC08 (1) 10.1 13.2 62.0
ZC09 (2) 9.0 9.0 9.0
ZC10 (2) 3.0 1.0 4.0
ZC11 (2) 10.0 NT 13.0
ZC12 (2) 11.0 9.0 7.0
ZC13 (2) 14.0 NT 13.0
a Determined as described elsewhere (16) and confirmed by enzyme-linked
immunosorbent assay.
b Determined by 51Cr release assay using autologous EBV-BCL infected with
control (sc11) or recombinant vaccinia virus expressing either HIV-1 nef or GPE.
Results are expressed as means for triplicate wells at an E:T ratio of 50:1 in all
subjects except ZC05 (25:1) and ZC01 (20:1), determined as (cpm sample 2 cpm
spontaneous)/(cpm Triton 2 cpm spontaneous) 3 100. Unlabeled sc11-infected
EBV-BCL were added to each well at a 20:1 to 40:1 unlabeled-to-labeled cell
ratio.
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